Stockscreener 앱 받기
0.9341
0.11%
-0.001
시간 외 거래:
.93
-0.0041
-0.44%
전일 마감가:
$0.9351
열려 있는:
$0.93
하루 거래량:
622.94K
Relative Volume:
1.04
시가총액:
$43.93M
수익:
-
순이익/손실:
$-40.56M
주가수익비율:
-0.7984
EPS:
-1.17
순현금흐름:
$-35.28M
1주 성능:
+0.04%
1개월 성능:
-8.42%
6개월 성능:
-32.31%
1년 성능:
-70.81%
1일 변동 폭
$0.9101
$0.9586
1주일 범위
$0.90
$1.16
52주 변동 폭
$0.8505
$3.405
Pds Biotechnology Corporation Stock (PDSB) Company Profile
명칭
Pds Biotechnology Corporation
전화
800-208-3343
주소
303A COLLEGE ROAD EAST, PRINCETON
PDSB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.9341 | 43.97M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-11-01 | 개시 | B. Riley Securities | Buy |
| 2021-06-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-11-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | 개시 | Alliance Global Partners | Buy |
| 2020-03-09 | 개시 | Noble Capital Markets | Outperform |
| 2019-10-24 | 개시 | Chardan Capital Markets | Buy |
모두보기
Pds Biotechnology Corporation 주식(PDSB)의 최신 뉴스
Will PDS Biotechnology Corporation stock go up soonEarnings Overview Summary & Free High Accuracy Swing Entry Alerts - newser.com
Is PDS Biotechnology Corporation stock positioned for long term growthJuly 2025 EndofMonth & Risk Adjusted Buy and Sell Alerts - newser.com
Will PDS Biotechnology Corporation stock reach all time highs in 2025Earnings Growth Summary & Safe Entry Trade Signal Reports - newser.com
Why PDS Biotechnology Corporation stock is recommended by analystsJuly 2025 Movers & Precise Swing Trade Entry Alerts - newser.com
Is PDS Biotechnology Corporation stock entering bullish territoryTrade Performance Summary & AI Forecast for Swing Trade Picks - newser.com
Is PDS Biotechnology Corporation stock a good choice for value investorsJuly 2025 PreEarnings & Consistent Profit Trading Strategies - newser.com
Earnings visualization tools for PDS Biotechnology CorporationTrend Reversal & Reliable Trade Execution Plans - newser.com
What machine learning models say about PDS Biotechnology CorporationCPI Data & Fast Moving Trade Plans - newser.com
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval - Stocktwits
Building trade automation scripts for PDS Biotechnology CorporationTrade Exit Report & Safe Capital Growth Tips - newser.com
Multi factor analysis applied to PDS Biotechnology CorporationMarket Sentiment Report & AI Based Trade Execution Alerts - newser.com
PDS Biotechnology Seeks Accelerated FDA Pathway for Cancer Therapy - AD HOC NEWS
What dividend safety score for PDS Biotechnology Corporation stockTrade Volume Summary & Fast Moving Market Watchlists - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedRate Hike & Low Drawdown Investment Strategies - newser.com
New Clinical and Translational Data on PDS Biotechnology’s Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting - The Manila Times
PDS Biotechnology Corporation Announces New Clinical and Translational Data on Pds0101 and Pds01adc to Be Presented At the 2025 Society for Immunotherapy of Cancer Annual Meeting - MarketScreener
PDS Biotech stock soars after seeking expedited approval pathway for cancer drug - Investing.com India
PDS Biotech to seek expedited approval pathway for PDS0101 in HPV16-positive head and neck cancer - MarketScreener
PDS Biotechnology Corporation Seeks Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer Following Promising VERSATILE-002 Trial Results - Quiver Quantitative
PDSB seeks FDA meeting to explore expedited path for PDS0101 - Stock Titan
39.3-month mOS seen with PDS0101 as PDS Biotech (NASDAQ: PDSB) seeks FDA expedited path - Stock Titan
Pds Biotechnology Corporation (PDSB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):